
Xencor Inc
XNCRHealthcare|Biotechnology|USA
$15.86
-0.27 (-1.64%)
Tangible Book
$6.86
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
77.89,
120.35,
140.67,
269.82,
539.16
],
"ebit_estimate": [
-272.48,
-285.17,
-297.46,
-213.74,
-93.95
],
"ebitda_estimate": [
-264.39,
-285.26,
-281.42,
-89.04,
-87.35
],
"net_income_estimate": [
-298.27,
-265.36,
-296.25,
-224.39,
-80.4
],
"per_share_eps_estimate": [
-3.83,
-3.16,
-3.18,
-1.99,
-0.2
],
"eps_nri_estimate": [
-3.95,
-3.23,
-3.18,
-1.99,
-0.2
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-305.39,
-284.17,
-296.07,
-201.17,
-78.66
],
"operating_cash_flow_per_share_estimate": [
-1.84,
-1.27,
null,
null,
null
],
"roa_estimate": [
-46.9,
-61.2,
null,
null,
null
],
"roe_estimate": [
-31.86,
-89.4,
null,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
93.33,
93.27
],
"operating_cash_flow_estimate": [
-138.45,
-95.56,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": -29.97,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": -30.09,
"future_eps_nri_estimate_growth": -29.97,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": -17.29,
"future_ebitda_estimate_growth": -17.84,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -40.31,
"future_pretax_income_estimate_growth": -42.09,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
20.06,
22.64,
30.96,
13.14,
13.29,
13.79,
14.02,
14.71
],
"ebit_estimate": [
-64.14,
-64.73,
-64.78,
-70.04,
-73.73,
-75.86,
-78.65,
-64.8
],
"ebitda_estimate": [
-65.6,
-65.17,
-64.18,
-63.73,
-63.64,
-63.7,
-63.72,
-62.24
],
"net_income_estimate": [
-61.42,
-60.12,
-52.92,
-70.46,
-74.28,
-76.62,
-79.55,
-64.8
],
"per_share_eps_estimate": [
-0.79,
-0.77,
-0.65,
-0.84,
-0.85,
-0.91,
-0.98,
-0.71
],
"eps_nri_estimate": [
-0.81,
-0.79,
-0.67,
-0.87,
-0.88,
-0.94,
-1.01,
-0.82
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-61.51,
-60.99,
-56.47,
-70.46,
-74.28,
-76.62,
-79.55,
-64.8
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
100,
100,
100,
100,
100
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": -29.97,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": -30.09,
"future_eps_nri_estimate_growth": -29.97,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": -17.29,
"future_ebitda_estimate_growth": -17.84,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -40.31,
"future_pretax_income_estimate_growth": -42.09,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}